[1] KUPIEC TC, ALOUMANIS V, BEN M, et al. Physical and chemical stability of esomeprazole sodium solutions[J]. Ann Pharmacother, 2008,42(9):1247-1251.
[2] 吕小娟, 艾伟鹏, 马林. 质子泵抑制剂预防危重症患者并发应激性溃疡的循证药物经济学评价[J].中国医院药学杂志,2015,35(24):2237-2240.
[3] UCHIYAMA T, HIGURASHI T, KURIYAMA H, et al. Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection[J]. World J Gastrointest Endosc, 2017,9(10):514-520.
[4] KAGAMI T, YAMADE M, SUZUKI T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype[J]. Clin Pharmacol Ther, 2018,103(5):906-913.
[5] 黄瑾, 刘正跃, 田泾. 长期大剂量使用质子泵抑制剂的严重不良反应和药学监护[J].中国医院药学杂志,2012,32(20):1648-1651.
[6] VIDELA R, SOMMARDAHL CS, ELLIOTT SB, et al. Effects of intravenously administered esomeprazole sodium on gastric juice pH in adult female horses[J]. J Vet Intern Med, 2011,25(3):558-562.
[7] 芦小燕, 戴幼琴, 陈维, 等. 基于循证的静脉用质子泵抑制剂预防应激性溃疡的合理性评价标准的建立[J].中国现代应用药学,2015,32(12):1481-1484.
[8] 吴明杰. 住院患者注射用质子泵抑制剂不合理应用分析[J].中国医院用药评价与分析,2016,16(02):257-259.
[9] MEI J, YU Y, MA J, et al. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms:a meta-analysis[J]. Pharmazie, 2016,71(5):285-291.
[10] ZHOU J, QUINLAN M, GLENN K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers[J]. Br J Clin Pharmacol, 2016,82(4):1022-1029.
[11] 孙敏, 黄坤明, 司继刚. 临床使用质子泵抑制剂的药学监护[J].河北医药,2016,38(02):275-278.
[12] 张石革. 质子泵抑制剂临床应用的药学监护[J].中国执业药师,2015,12(07):31-37.